BIOMAT Database Logo BIOMAT Database Logo

Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078. 1998

S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
The Institute for Cancer Research, Faculty of Medicine, Kagoshima University, Sakuragaoka, Japan.

The leukotriene D4 (LTD4) receptor antagonist, 4-oxo-8-[p-(4-phenylbutyloxy)benzoylamino]-2-(tetrazol-5-yl) -4H-1-benzopyran hemihydrate (ONO-1078) is used for the treatment of allergic asthma and other immediate hypersensitivity diseases. We examined the effect of ONO-1078 on the sensitivity to vincristine (VCR) of MRP overexpressing multidrug-resistant CV60 and its parental drug-sensitive KB-3-1 cell lines. The sensitivity to VCR of KB-3-1 and CV60 cells was increased 13- and 15-fold, respectively, by ONO-1078 at the maximum non-toxic concentration (100 microM). The VCR sensitivity of multidrug-resistant KB-C2 cells that overexpressed P-gp was increased 2.6-fold by ONO-1078. The accumulation of VCR in KB-3-1, CV60 and KB-C2 cells was significantly increased by ONO-1078. The efflux of VCR from KB-3-1 cells was not inhibited, but that from CV60 cells was enhanced compared with that from KB-3-1 cells and was partially inhibited by ONO-1078. ONO-1078 competitively inhibited the ATP-dependent [3H]LTC4 uptake in membrane vesicles isolated from CV60 cells. These findings suggest that ONO-1078 inhibits the transporting activity of MRP and that ONO-1078 increases the sensitivity to VCR of KB-3-1 cells by increasing the VCR uptake in the cells.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D002867 Chromones 1,4-Benzopyrones,Chromone,1,4 Benzopyrones
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D014750 Vincristine An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Leurocristine,Citomid,Farmistin,Oncovin,Oncovine,Onkocristin,Vincasar,Vincasar PFS,Vincristin Bristol,Vincristin medac,Vincristine Sulfate,Vincrisul,Vintec,cellcristin,PFS, Vincasar,Sulfate, Vincristine
D017998 Leukotriene D4 One of the biologically active principles of SRS-A. It is generated from LEUKOTRIENE C4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability. (From Dictionary of Prostaglandins and Related Compounds, 1990) LTD4,Leukotriene D,Leukotriene D-4,Leukotrienes D,Leukotriene D 4
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D020024 Leukotriene Antagonists A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. Leukotriene Antagonist,Leukotriene Receptor Antagonist,Leukotriene Receptor Antagonists,Antagonists, Leukotriene,Receptor Antagonists, Leukotriene,Antagonist, Leukotriene,Antagonist, Leukotriene Receptor,Antagonists, Leukotriene Receptor,Receptor Antagonist, Leukotriene

Related Publications

S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078.
July 1994, American journal of respiratory and critical care medicine,
S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.
August 2001, Internal medicine (Tokyo, Japan),
S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein.
October 1998, Biochemical and biophysical research communications,
S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
Inhibition of human eosinophil activation by a cysteinyl leukotriene receptor antagonist (pranlukast; ONO-1078).
June 2003, The Journal of asthma : official journal of the Association for the Care of Asthma,
S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
Inhibition by a novel peptide leukotriene receptor antagonist ONO-1078 of airway wall thickening and airway hyperresponsiveness to histamine induced by leukotriene C4 or leukotriene D4 in guinea-pigs.
October 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
Effect of a peptide leukotriene receptor antagonist, ONO-1078, on guinea-pig models of asthma.
April 1993, European journal of pharmacology,
S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats.
October 2002, Acta pharmacologica Sinica,
S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
[Inhibitory effect of ONO-1078, a novel leukotriene receptor antagonist, on human peripheral blood eosinophils].
November 1996, Arerugi = [Allergy],
S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
Inhibition of endogenous leukotriene-mediated lung anaphylaxis in guinea pigs by a novel receptor antagonist ONO-1078.
January 1990, International archives of allergy and applied immunology,
S Nagayama, and Z S Chen, and M Kitazono, and Y Takebayashi, and K Niwa, and K Yamada, and A Tani, and M Haraguchi, and T Sumizawa, and T Furukawa, and T Aikou, and S Akiyama
Effects of a new thromboxane A2-antagonist (ONO-3708) and a new leukotriene-antagonist (ONO-1078) on thromboxane A2 analogue-, leukotriene C4-, and D4-induced regional myocardial blood flow reduction.
January 1988, Heart and vessels,
Copied contents to your clipboard!